CO6630085A2 - Tratamiento de artritis reumatoide con combinacion de laquinimod y metotrexato - Google Patents
Tratamiento de artritis reumatoide con combinacion de laquinimod y metotrexatoInfo
- Publication number
- CO6630085A2 CO6630085A2 CO12159942A CO12159942A CO6630085A2 CO 6630085 A2 CO6630085 A2 CO 6630085A2 CO 12159942 A CO12159942 A CO 12159942A CO 12159942 A CO12159942 A CO 12159942A CO 6630085 A2 CO6630085 A2 CO 6630085A2
- Authority
- CO
- Colombia
- Prior art keywords
- methotrexate
- laquinimod
- rheumatoid arthritis
- combination
- treating
- Prior art date
Links
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title abstract 4
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004577 laquinimod Drugs 0.000 title abstract 4
- 229960000485 methotrexate Drugs 0.000 title abstract 4
- 206010039073 rheumatoid arthritis Diseases 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención proporciona un método para tratar un sujeto que padece de artritis reumatoide que comprende administrar periódicamente al sujeto una cantidad de laquinimod o sal farmacéuticamente aceptable del mismo y una cantidad de metotrexato en donde las cantidades cuando se toman juntas son efectivas para tratar al sujeto. Esta invención también proporciona laquinimod o sal farmacéuticamente aceptable del mismo para uso en combinación con metotrexato al tratar un sujeto que padece de artritis reumatoide. Esta invención también proporciona una composición farmacéutica que comprende una cantidad de laquinimod o sal farmacéuticamente aceptable del mismo y una cantidad de metotrexato para uso al tratar un sujeto que padece de artritis reumatoide.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33937510P | 2010-03-03 | 2010-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6630085A2 true CO6630085A2 (es) | 2013-03-01 |
Family
ID=44531858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12159942A CO6630085A2 (es) | 2010-03-03 | 2012-09-17 | Tratamiento de artritis reumatoide con combinacion de laquinimod y metotrexato |
Country Status (21)
Country | Link |
---|---|
US (1) | US8501766B2 (es) |
EP (1) | EP2542079B1 (es) |
JP (1) | JP5819328B2 (es) |
KR (1) | KR20130014523A (es) |
CN (2) | CN105796556A (es) |
AU (1) | AU2011223697B2 (es) |
BR (1) | BR112012022187A2 (es) |
CA (1) | CA2791709A1 (es) |
CL (1) | CL2012002424A1 (es) |
CO (1) | CO6630085A2 (es) |
DK (1) | DK2542079T3 (es) |
EA (1) | EA201290860A1 (es) |
ES (1) | ES2476368T3 (es) |
MX (1) | MX2012010066A (es) |
NZ (1) | NZ602478A (es) |
PE (1) | PE20130690A1 (es) |
PT (1) | PT2542079E (es) |
SG (1) | SG183513A1 (es) |
SI (1) | SI2542079T1 (es) |
WO (1) | WO2011109531A1 (es) |
ZA (1) | ZA201207128B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101440982B1 (ko) * | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
ZA200810790B (en) | 2006-06-12 | 2010-03-31 | Teva Pharma | Stable laquinimod preparations |
DK2234485T3 (da) | 2007-12-20 | 2014-02-10 | Teva Pharma | Stabile laquinimod-præparater |
CN104311486A (zh) * | 2008-09-03 | 2015-01-28 | 泰华制药工业有限公司 | 2-羰基-1,2-二氢喹啉免疫功能调节剂 |
PT2442651E (pt) * | 2009-06-19 | 2015-10-22 | Teva Pharma | Tratamento da esclerose múltipla com laquinimod |
DK2458992T3 (en) * | 2009-07-30 | 2016-02-08 | Teva Pharma | Treatment of crohn's disease with laquinimod |
ES2586843T3 (es) | 2009-08-10 | 2016-10-19 | Teva Pharmaceutical Industries Ltd. | Tratamiento de trastornos relacionados con BDNF usando laquinimod |
AU2011223692A1 (en) * | 2010-03-03 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus nephritis using laquinimod |
NZ606587A (en) | 2010-07-09 | 2015-03-27 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
EA201490748A1 (ru) | 2011-10-12 | 2014-12-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение рассеянного склероза комбинацией лахинимода и финголимода |
BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
BR112014020372A8 (pt) | 2012-02-16 | 2018-01-23 | Teva Pharma | n-etil-n-fenil-1,2-di-hidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, preparação e utilização do mesmo |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
WO2014152009A1 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Transdermal formulations of laquinimod |
SG11201506409RA (en) | 2013-03-14 | 2015-09-29 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
CA2945978A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
CN115281149A (zh) * | 2021-05-12 | 2022-11-04 | 四川大学华西医院 | 一种临床前类风湿关节炎(Pre-RA)小鼠模型 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2340735A1 (fr) * | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
US5540934A (en) * | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
US5912349A (en) * | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
US6696407B1 (en) * | 1997-03-21 | 2004-02-24 | The Regents Of The University Of California | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6133285A (en) * | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
RS51019B (sr) * | 1999-10-25 | 2010-10-31 | Active Biotech Ab. | Lekovi za lečenje malignih tumora |
US6852323B2 (en) * | 2000-07-21 | 2005-02-08 | The Regents Of The University Of California | Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder |
US6307050B1 (en) * | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
US7560557B2 (en) * | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
US6875869B2 (en) * | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US20070292461A1 (en) * | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
UY28391A1 (es) * | 2003-06-25 | 2004-12-31 | Elan Pharm Inc | Metodos y composiciones para tratar artritis reumatoide |
US8795693B2 (en) * | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8314124B2 (en) * | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
CA2561164A1 (en) * | 2004-04-01 | 2005-10-20 | Elan Pharmaceuticals, Inc. | Steroid sparing agents and their use |
WO2006029036A2 (en) * | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
PL1797109T3 (pl) * | 2004-09-09 | 2016-11-30 | Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania | |
US20060205822A1 (en) * | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
AU2006344395B2 (en) * | 2005-10-13 | 2013-05-02 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive diseases |
US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
KR101440982B1 (ko) * | 2005-10-19 | 2014-09-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 제조방법 |
PT1951674E (pt) * | 2005-10-26 | 2011-12-19 | Merck Serono Sa | Derivados de sulfonamida e sua utilização para a modulação de metaloproteinases |
US20080108641A1 (en) * | 2006-02-08 | 2008-05-08 | Ajami Alfred M | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers |
US8367629B2 (en) * | 2006-02-14 | 2013-02-05 | Noxxon Pharma Ag | MCP-1 binding nucleic acids and use thereof |
JP2009528359A (ja) * | 2006-02-28 | 2009-08-06 | エラン ファーマシューティカルズ,インコーポレイテッド | ナタリズマブを用いて炎症性疾患および自己免疫性疾患を治療する方法 |
JP2009531304A (ja) * | 2006-02-28 | 2009-09-03 | エラン ファーマシューティカルズ,インコーポレイテッド | α−4阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法 |
RS20080391A (en) * | 2006-03-03 | 2009-07-15 | Elan Pharmaceuticals Inc., | Methods of treating inflammatory and autoimmune diseases with natalizumab |
US9399061B2 (en) * | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
WO2007139887A2 (en) | 2006-05-22 | 2007-12-06 | Cargill, Incorporated | Methods for treating bone or joint inflammation |
US20080118553A1 (en) * | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
ZA200810790B (en) * | 2006-06-12 | 2010-03-31 | Teva Pharma | Stable laquinimod preparations |
WO2008021368A2 (en) * | 2006-08-11 | 2008-02-21 | The Johns Hopkins University | Compositions and methods for neuroprotection |
CN101743018A (zh) | 2006-12-19 | 2010-06-16 | 梅里麦克药品公司 | 甲胎蛋白和免疫调谐剂的共同施用以治疗多发性硬化 |
US20100136125A1 (en) | 2006-12-28 | 2010-06-03 | Jacobus Pharmaceutical Company, Inc. | Method of treating inflammatory bowel disease |
CA2970273C (en) * | 2007-07-11 | 2020-04-14 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
DK2234485T3 (da) * | 2007-12-20 | 2014-02-10 | Teva Pharma | Stabile laquinimod-præparater |
CN104311486A (zh) * | 2008-09-03 | 2015-01-28 | 泰华制药工业有限公司 | 2-羰基-1,2-二氢喹啉免疫功能调节剂 |
BRPI0920927A2 (pt) | 2008-11-13 | 2019-09-24 | Link Medicine Corp | derivados de azaquinolinona e usos dos mesmos |
PT2442651E (pt) * | 2009-06-19 | 2015-10-22 | Teva Pharma | Tratamento da esclerose múltipla com laquinimod |
DK2458992T3 (en) * | 2009-07-30 | 2016-02-08 | Teva Pharma | Treatment of crohn's disease with laquinimod |
ES2586843T3 (es) * | 2009-08-10 | 2016-10-19 | Teva Pharmaceutical Industries Ltd. | Tratamiento de trastornos relacionados con BDNF usando laquinimod |
AU2011223692A1 (en) * | 2010-03-03 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus nephritis using laquinimod |
PL2542080T3 (pl) * | 2010-03-03 | 2017-02-28 | Teva Pharmaceutical Industries Ltd. | Leczenie toczniowego zapalenia stawów z zastosowaniem lakwinimodu |
NZ606587A (en) * | 2010-07-09 | 2015-03-27 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
NZ606589A (en) * | 2010-07-09 | 2015-03-27 | Teva Pharma | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
CA2820586A1 (en) * | 2010-12-07 | 2012-06-14 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
CN103781355A (zh) | 2011-07-28 | 2014-05-07 | 泰华制药工业有限公司 | 用拉喹莫德与干扰素-β的组合治疗多发性硬化症 |
JP2014521658A (ja) | 2011-07-28 | 2014-08-28 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
-
2011
- 2011-03-02 KR KR1020127025006A patent/KR20130014523A/ko not_active Application Discontinuation
- 2011-03-02 DK DK11751300.2T patent/DK2542079T3/da active
- 2011-03-02 CN CN201610240474.2A patent/CN105796556A/zh active Pending
- 2011-03-02 SG SG2012063491A patent/SG183513A1/en unknown
- 2011-03-02 PT PT117513002T patent/PT2542079E/pt unknown
- 2011-03-02 WO PCT/US2011/026885 patent/WO2011109531A1/en active Application Filing
- 2011-03-02 JP JP2012556213A patent/JP5819328B2/ja not_active Expired - Fee Related
- 2011-03-02 NZ NZ602478A patent/NZ602478A/en not_active IP Right Cessation
- 2011-03-02 EA EA201290860A patent/EA201290860A1/ru unknown
- 2011-03-02 US US13/039,188 patent/US8501766B2/en not_active Expired - Fee Related
- 2011-03-02 CA CA2791709A patent/CA2791709A1/en not_active Abandoned
- 2011-03-02 ES ES11751300.2T patent/ES2476368T3/es active Active
- 2011-03-02 BR BR112012022187A patent/BR112012022187A2/pt not_active IP Right Cessation
- 2011-03-02 SI SI201130210T patent/SI2542079T1/sl unknown
- 2011-03-02 CN CN2011800121091A patent/CN102781240A/zh active Pending
- 2011-03-02 MX MX2012010066A patent/MX2012010066A/es active IP Right Grant
- 2011-03-02 AU AU2011223697A patent/AU2011223697B2/en not_active Ceased
- 2011-03-02 EP EP11751300.2A patent/EP2542079B1/en active Active
- 2011-03-02 PE PE2012001383A patent/PE20130690A1/es not_active Application Discontinuation
-
2012
- 2012-08-31 CL CL2012002424A patent/CL2012002424A1/es unknown
- 2012-09-17 CO CO12159942A patent/CO6630085A2/es unknown
- 2012-09-21 ZA ZA2012/07128A patent/ZA201207128B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2011223697B2 (en) | 2016-07-14 |
ZA201207128B (en) | 2014-04-30 |
EP2542079A4 (en) | 2013-07-24 |
SI2542079T1 (sl) | 2014-08-29 |
JP2013521304A (ja) | 2013-06-10 |
ES2476368T3 (es) | 2014-07-14 |
EA201290860A1 (ru) | 2013-04-30 |
BR112012022187A2 (pt) | 2015-09-22 |
CL2012002424A1 (es) | 2012-12-21 |
MX2012010066A (es) | 2012-10-03 |
JP5819328B2 (ja) | 2015-11-24 |
EP2542079B1 (en) | 2014-05-21 |
KR20130014523A (ko) | 2013-02-07 |
DK2542079T3 (da) | 2014-08-25 |
US20110218203A1 (en) | 2011-09-08 |
PE20130690A1 (es) | 2013-07-07 |
PT2542079E (pt) | 2014-07-18 |
CA2791709A1 (en) | 2011-09-09 |
AU2011223697A1 (en) | 2012-10-11 |
CN105796556A (zh) | 2016-07-27 |
SG183513A1 (en) | 2012-09-27 |
WO2011109531A1 (en) | 2011-09-09 |
NZ602478A (en) | 2014-09-26 |
CN102781240A (zh) | 2012-11-14 |
US8501766B2 (en) | 2013-08-06 |
EP2542079A1 (en) | 2013-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6630085A2 (es) | Tratamiento de artritis reumatoide con combinacion de laquinimod y metotrexato | |
CO6630086A2 (es) | Tratamiento de artritis por lupus usando laquinimod | |
CY1121850T1 (el) | Διαρυλο μακροκυκλοι ως ρυθμιστες των πρωτεϊνικων kinασων | |
CO6630082A2 (es) | Tratamiento de lupus nefritis usando laquinimod | |
BR112014028017A2 (pt) | composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror | |
EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
MX2014004766A (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
MX2013009679A (es) | Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso. | |
EA201492216A1 (ru) | Ингибиторы бромодомена и их применение | |
BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
BR112013002484A2 (pt) | composto, composição farmacêutica, métodos para tratar esclerose múltipla e artrite reumatoide, e, uso de um composto. | |
CY1113640T1 (el) | Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας | |
UY34387A (es) | Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización. | |
BR112014011254A2 (pt) | 2-tiopirimidinonas | |
NI201600021A (es) | Inhibidores de rorc2 heterobicicloarilo y sus métodos de uso | |
EA201201201A1 (ru) | Новые ингибиторы rock | |
BR112014000634A2 (pt) | métodos para tratamento de incontinência associada com atividade sexual | |
AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
CY1116234T1 (el) | Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
AR086390A1 (es) | Metodo para el tratamiento de malignidades solidas que incluyen malignidades solidas avanzadas o metastasicas | |
EA201390616A1 (ru) | ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2 | |
BR112015019564A2 (pt) | tratamento de esclerose múltipla com laquinimod | |
EA201171414A1 (ru) | Ингибиторы белков семейства iap | |
BR112013024137A2 (pt) | composições de antagonistas de opióides e seu uso para o tratamento da esclerodermia | |
IT1401083B1 (it) | Composizione per il trattamento e la prevenzione dell'herpes simplex labiale. |